Business description
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
Management board & Supervisory board
| CEO |
| Prof. Dr. Dolores J. Schendel |
| Management board |
| Axel-Sven Malkomes |
| Supervisory board |
| Dr. Gerd Zettlmeissl, Antoinette Hiebeler-Hasner, Dr. Anthony Man, Dr. Frank Mathias, Dr. Keith Manchester, Ronald Scott |
Company data
| Name: |
Medigene AG |
| Address: |
Lochhamer Str. 11,D-82152 Planegg/Martinsried |
| Phone: |
+49-89-200033-0 |
| Fax: |
+49-89-200033-2920 |
| E-mail: |
medigene@medigene.com
|
| Internet: |
www.medigene.com |
| Industry: |
Biotechnology |
| Sector: |
Biotechnology |
| Sub sector: |
Biotechnology |
| End of financial year: |
12-31 |
| Free Float: |
85.50% |
| IPO date: |
2000-06-30 |
Investor relations
| Name: |
Dr. Anna Niedl |
| IR phone: |
+49-89-200033-3301 |
| IR Fax: |
- |
| IR e-mail: |
investor@medigene.com
|
